The latest batch of applications for US FDA approval touch on some of the major drug development themes of 2022, from the resurgence of big pharma vaccine R&D to the popularity of rare disease programs.
Pfizer Inc.’s high-profile development of the COVID-19 vaccine Comirnaty with BioNTech SE has overshadowed some of the company’s investment in novel vaccine research, but the current “tripledemic” of COVID, respiratory syncytial virus and influenza highlights the company’s latest BLA submission, for an RSV vaccine for older adults
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?